ClinicalTrials.gg
Status unknownNCT03495739Updated Apr 12, 2018

Clinical Trial to Assess the Safety and Pharmacokinetics of RDG-17012 Capsule and Pradaxa® Capsule in Healthy Male Volunteers

A Phase 1 interventional study of RDG-17012 Capsule and Dabigatran Etexilate Mesylate 150 MG Oral Capsule in Healthy, sponsored by Huons Co., Ltd.. Status unknown at 1 site in Korea, Republic of. Open to male participants aged 19 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-04-12.

Sponsored by Huons Co., Ltd. (part of Huons Global) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2018), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
19 Years and older
Sex
Male
01

Study summary

A randomized, open-label, single-dosing, 2x2 crossover study, the safety and pharmacokinetics of RDG-17012 with Pradaxa® in healthy male volunteers

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Huons Co., Ltd. is the lead sponsor of 29 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 19 to 45, healthy male subjects(at screening)
  • Subject without a hereditary problems, chronic disease and morbid symptom
  • Volunteer who totally understands the progress of this clinical trials, make decision by his free will, and signed a consent form to follow the progress

Exclusion criteria

Exclusion Criteria:

  • Volunteer who has past or present history of any diseases following below.(liver, kidney,digestive system, pulmonary,hematooncology, endocrine, urinary,neurology,mental disorder, skeletomuscular, immunology, otolaryngology,cardiovascular)
  • Exceed 2 times the normal range of , ALT, Total at screening test
  • History of drug abuse, or a positive urine drug screen
  • Regular alcohol consumption(over 21 units/week, 1unit=10g of pure alcohol) or volunteers who cannot abstain from drinking during the study
  • Any condition that, in the view of the investigator, would interfere with study participation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Experimental
    RDG-17012® capsule

    RDG-17012 ® capsule(dabigatran etexilate tosylate)

    Drug: RDG-17012 Capsule

  • Active comparator
    Pradaxa® capsule

    Pradaxa® capsule(dabigatran etexilate mesylate)

    Drug: Dabigatran Etexilate Mesylate 150 MG Oral Capsule

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under Curve(AUC) last of Total dabigatran and Free dabigatran

    Time frame: (Day0)0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12hour, Day 1, Day2

  2. Maximum of concentration(Cmax) of Total dabigatran and Free dabigatran

    Time frame: (Day0)0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12hour, Day 1, Day2

Secondary outcomes

  1. Area Under Curve(AUC)inf of Total dabigatran and Free dabigatran

    Time frame: (Day0)0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12hour, Day 1, Day2

07

Study locations

1 site
  • Huons
    Gyeonggi-do, Seongnam-si 13486, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Feb 2018 (actual). Primary completion is estimated for Jun 2018, 4 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2018
First posted
Apr 12, 2018
StartActual
Feb 1, 2018
Primary completionEst.
Jun 1, 2018
CompletionEst.
Dec 1, 2018
Last update
Apr 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03495739
Lead sponsor
Huons Co., Ltd.
Responsible party
Sponsor
First posted
Apr 12, 2018
Start date
Feb 1, 2018
Primary completion
Jun 1, 2018 (estimated)
Completion
Dec 1, 2018 (estimated)
Last update
Apr 12, 2018

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion